Spending power
TheGrid Corporate Spending Power index would rate purchasing capacity from registry, scale and activity signals.
Spending power
Key facts
Counted staff
8
self-reported band not used
Founded
2018
8 years
Legal entities
None matched
Office countries
1
1 address
Funding rounds
5
Series B · Oct 2025
Company type
Privately Held
self-reported
Description
CytoNiche™ is revolutionizing the cell and gene therapy (CGT) industry with its scalable 3D FloTrix™ technology, offering comprehensive solutions for CGT manufacturing. Our product portfolio includes GMP-grade dissolvable microcarriers, serum-free media for mesenchymal stromal/stem cells, and a complete suite of GMP-compliant equipment and consumables. These solutions support every stage of cell production—from expansion and harvesting to processing and filling.
Driven by a vision to ignite a new era in industrial cell development, we are empowering CGT advancements through intelligent, 3D cellular mass manufacturing technology. This innovation not only reduces production time and costs but also improves scalability, making it possible to produce billions of high-quality cells more efficiently than traditional methods.
Backed by extensive industry experience and supported by FDA Master Files, our core technology is already being used in several upcoming registered clinical trials, as well as in a successfully commercialized therapeutic. Whether you're working with mesenchymal stem cells (MSCs), exosomes, or other future technologies based on adherent cells, our systems are designed to meet the growing demands of the CGT field.
By reducing facility footprint, labor costs, and contamination risks, our technology is helping shape the future of sustainable biomanufacturing, bringing us closer to benefiting more patients around the world.
Specialties
All 7 specialties
- cell culture
- cell therapy
- gene therapy
- 3D Cell Culturing
- stem cells
- regenerative medicine
- tissue engineering
Locations
Country footprint
Show as table · Offices in 1 country
| Countries | 1 |
|---|---|
| Primary country | SG |
All codes: SG
Addresses
- SG1 FUSIONOPOLIS LINK #06-06 NEXUS@ONE-NORTH; Singapore, 138542Primary
Grid intelligence Members
Funding
Last round · 15 October 2025Amount not recordedSeries B
Rounds5
Round typeSeries B · venture round
Amount (USD)not recorded
Stage rank4
Investors named0
Since last round3 mo
Funding
Show as table · 5 funding rounds
| Rounds | 5 |
|---|---|
| Axis | 2018 to 2026 |
| Series B · 15 Oct 2025 | not disclosed |
Dated rounds only. The axis ends at the date this profile was last observed, not at today.
Signals & hiring
Hiring, headcount and registry-change signals, streamed to members.
Latest signal
Hiring activity
Headcount trend
Financials
Registry-filed capital and financial indicators, standardised by TheGrid.
Paid-up capital
Fiscal period
Registered charges
Revenue
Profit / loss
People & contacts
4 employee profiles on record · names withheld.
Names and titles are intentionally absent from this page. The source relation carries no consent record across the privacy regimes this directory spans, so it is never requested and never stored. Search engines see exactly what you see here.
Names are withheld until a consented source exists.
FAQ
How many people work at CytoNiche?
8 counted staff profiles at January 2026. The brand's self-reported band sits above that count and is not published as a headcount.
Where does CytoNiche have offices?
One address on record, Singapore only. Primary: 1 FUSIONOPOLIS LINK #06-06 NEXUS@ONE-NORTH, Singapore 138542.
Has CytoNiche raised funding?
Five rounds. Latest 15 October 2025: Series B, no amount recorded.
What does CytoNiche list as its specialties?
Seven tags on the brand's own list, among them regenerative medicine.
Which companies are listed alongside CytoNiche?
One peer profile on record: SingCell.